Valuation: SANA AB

Market Cap 1.31B 131M 115M 109M 98.94M 186M 12.58B 187M 504M 6.42B 492M 481M 20.8B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.31B 131M 115M 109M 98.94M 186M 12.58B 187M 504M 6.42B 492M 481M 20.8B EV / Sales 2026 *
12.7x
EV / Sales 2027 * 6.24x
Free-Float
90.64%
Yield 2026 *
-
Yield 2027 * -
1 day-2.63%
1 week-5.45%
Current month-17.35%
1 month-20.61%
3 months-27.27%
6 months-37.55%
Current year-55.40%
1 week 9.45
Extreme 9.45
10.34
1 month 9.45
Extreme 9.45
12.11
Current year 9.45
Extreme 9.45
28.3
1 year 9.45
Extreme 9.45
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 A Buy

Chairman

50,000 0.0362%
9/1/26 A Buy

Founder

9,000 0.0065%
8/28/26 A Buy

Chief Financial Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-2.63%-5.45%-23.00%+50.80% 135M
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-3.08%+37.74%+84.21% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-1.94%-14.13%+354.32% 25.73B
+0.57%+3.14%+1.02%-3.92% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+0.02%+49.51%+163.05% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average -0.47%-0.41%+31.40%+153.69% 27.53B
Weighted average by Cap. -0.12%-1.05%+38.10%+125.25%

Financials

2026 *2027 *
Net sales 103M 10.36M 9.11M 8.61M 7.82M 14.69M 994M 14.77M 39.79M 507M 38.87M 38.03M 1.64B 209M 21.01M 18.48M 17.48M 15.86M 29.8M 2.02B 29.96M 80.74M 1.03B 78.87M 77.17M 3.33B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
44
Date Price Change Volume
28/09/26 SEK 9.455 -2.63% 381,393
25/09/26 SEK 9.710 -1.12% 379,612
24/09/26 SEK 9.820 -0.81% 387,361
23/09/26 SEK 9.900 -1.69% 259,760
22/09/26 SEK 10.07 +5.45% 443,585

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock